The Priority Review

Tag

LLSAT

1 story

  1. Clinical trials

    GlaxoSmithKline registers Phase 3 linerixibat safety eXtension study in Japan

    The study plans to enroll 40 participants and start on October 9, 2026. It aims to assess the long-term safety of linerixibat in Japanese adults with cholestatic pruritus in primary biliary cholangitis (PBC) who previously participated in the linerixibat long-term safety and efficacy study, LLSAT (NCT04167358).